Underarm Testosterone Therapy Cleared
WASHINGTON, D.C.—The FDA has approved the first and only testosterone therapy applied to the underarm.
WASHINGTON, D.C.—The FDA has approved the first and only testosterone therapy applied to the underarm.
WASHINGTON, D.C.—Statin use by hyperlipidemic patients may decrease the risk of urinary stone formation, according to study findings presented at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Silodosin may be an effective treatment for moderate or severe chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), researchers reported at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Adjuvant use of tamsulosin or nifedipine after extracorporeal shock wave lithotripsy (SWL) improves stone free rates in patients treated for non-lower pole renal stones 10-20 mm in diameter, Brazilian researchers reported at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Intratumoral C-reactive protein (CRP) may be a robust biomarker of prognosis in patients with local renal cell carcinoma (RCC), investigators reported at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Pre-cystectomy smoking habits influence survival following radical cystectomy for bladder cancer, according to researchers.
WASHINGTON, D.C.—Renal masses greater than 4 cm in diameter tend to grow faster than smaller masses, a researcher reported at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Elevated serum uric acid levels may be a marker for an increased risk of erectile dysfunction (ED), Iranian researchers reported at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—A urologist told attendees of the American Urological Association 2011 annual meeting he has had promising results using cyclosporine A off-label to treat patients with severely symptomatic refractory interstitial cystitis (IC).
WASHINGTON, D.C.—The rate of partial nephrectomy (PN) performed on patients with renal cell carcinoma (RCC) has increased nearly fourfold from 1998 to 2007 in the United States, but it is still underused, researchers reported at the American Urological Association 2011 annual meeting.